NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD

This study has been completed.
Information provided by:
Imperial College London Identifier:
First received: September 9, 2005
Last updated: June 3, 2015
Last verified: April 2008
The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, induced sputum, nasal lavage and mouth wash fluid in healthy non-smokers, current smokers and patients with COPD.

Condition Intervention
Healthy Volunteers (Non-smoker)
Healthy Volunteers (Smoker)
Chronic Obstructive Pulmonary Disease
Procedure: Inhalation of aminoguanidine and oral intake and inhalation of L-arginine
Procedure: Exhaled Breath Condensate
Procedure: Nasal Nitric Oxide
Procedure: Nasal Lavage
Procedure: Spirometry

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Official Title: A Double Blind, Crossover Placebo-controlled Study to Evaluate the Effect of L-arginine and Aminoguanidine on Bronchial and Alveolar Nitric Oxide and Nitric Oxide Metabolites in Exhaled Air, Breath Condensate, Nasal Lavage, Mouth Wash Fluid, and Induced Sputum in 7 Healthy Non-smokers, 10 Smokers and 12 COPD Patients

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • nitric oxide

Estimated Enrollment: 29
Study Start Date: October 2003
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy non-smokers
  • Normal spirometry (FEV1 >90 % predicted; exhaled NO bigger than or equal to 10 ppb; flow 50 ml/s)
  • At risk (current smokers)

    • Normal spirometry, with or without chronic symptoms (cough, sputum production)
    • FEV1 reversibility of <15% after inhaled beta2-agonists*
  • Moderate COPD

    • FEV1 greater than or equal to 30% and < 80%
    • FEV1/FVC < 70% predicted
    • FEV1 reversibility of <15% after inhaled beta2-agonists
    • With or without chronic symptoms (cough, sputum production, dyspnea)
  • Able to comprehend and grant a written informed consent

Exclusion Criteria:

  • Concomitant use or pre-treatment within the last 4 weeks with oral steroids
  • Respiratory infection within 4 weeks prior to entry into the trial
  • Females who are pregnant or lactating
  • History of current or past drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180635

United Kingdom
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY
Sponsors and Collaborators
Imperial College London
Principal Investigator: Sergei A Kharitonov, MD PhD Imperial College London
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00180635     History of Changes
Other Study ID Numbers: 02-104-170903 
Study First Received: September 9, 2005
Last Updated: June 3, 2015
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Nitric Oxide
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Endothelium-Dependent Relaxing Factors
Enzyme Inhibitors
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Vasodilator Agents processed this record on May 24, 2016